Plasma and urinary CP I and CP III concentrations in chimeric mice with human hepatocytes after rifampicin administration
Pharmacology Research & Perspectives · 2024
DOI: 10.1002/prp2.70017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Yurina Shishido und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Research Laboratories, Toray Industries, Inc., Kamakura, Kanagawa, Japan. Hauptthemen laut MEDLINE: Rifampin, Hepatocytes, Mice, Inbred ICR, Coproporphyrins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The interest in transporter‐mediated drug interactions has been increasing in the field of drug development. In this study, we measured the plasma and urinary concentrations of coproporphyrin (CP) I and CP III as endogenous substrates for organic anion‐transporting polypeptide (OATP) using chimeric mice with human hepatocytes (PXB mice) and examined the influence of an OATP inhibitor, rifampicin (RIF). CP I and CP III were actively taken up intracellularly, and RIF inhibited the uptake in a concentration‐dependent manner for both CP I and CP III in human hepatocytes (PXB‐cells). Single doses of RIF at 10 and 30 mg/kg were orally or intravenously administered to PXB mice and wild‐type ICR mice. Plasma concentrations (AUC 0‐8h ) of CP I increased in both mice. However, a marked increase in CP III was only observed in ICR mice, after intravenous administration of RIF at 30 mg/kg. The IC 50 values of RIF for intracellular CP I/III uptake and the unbound plasma concentrations of RIF suggested that the increase in plasma CP I is associated with the exposure of RIF to OATPs. The 24‐h cumulative urinary excretions of CP I and CP III increased in both mice, but more markedly in PXB mice. Thus, RIF increased the plasma and urinary concentrations of CP I and CP III in the mice, as reported in humans, and CP I may be a more sensitive biomarker of OATP‐mediated drug interactions in PXB mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Research Laboratories, Toray Industries, Inc., Kamakura, Kanagawa, Japan.
ORCID-Profile: Masashi Uchida
Zitieren
APA
Shishido, Y., Yoshida, T., Oshida, K., & Uchida, M. (2024). Plasma and urinary CP I and CP III concentrations in chimeric mice with human hepatocytes after rifampicin administration. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70017
Vancouver
Shishido Y, Yoshida T, Oshida K, Uchida M. Plasma and urinary CP I and CP III concentrations in chimeric mice with human hepatocytes after rifampicin administration. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.70017
BibTeX
@article{Shishido2024,
author = {Shishido, Yurina and Yoshida, Tomohiro and Oshida, Keiyu and Uchida, Masashi},
title = {Plasma and urinary CP I and CP III concentrations in chimeric mice with human hepatocytes after rifampicin administration},
journal = {Pharmacology Research & Perspectives},
year = {2024},
doi = {10.1002/prp2.70017}
}
EUVIMED